Last reviewed 2026-05-14 · How we verify

Placebo to GSK3196165/ Sarilumab

Placebo to GSK3196165/ Sarilumab is a IL-6 receptor antagonist Small molecule drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Rheumatoid arthritis (moderate to severe), COVID-19 (severe pneumonia).

Sarilumab is a monoclonal antibody that blocks the interleukin-6 receptor (IL-6R), reducing inflammatory signaling in immune-mediated diseases.

Sarilumab is a monoclonal antibody that blocks the interleukin-6 receptor (IL-6R), reducing inflammatory signaling in immune-mediated diseases. Used for Rheumatoid arthritis (moderate to severe), COVID-19 (severe pneumonia).

At a glance

Mechanism of action

Sarilumab binds to and inhibits the IL-6 receptor on immune cells and other tissues, preventing IL-6-mediated inflammation. This mechanism suppresses the production of inflammatory cytokines and reduces systemic inflammation, making it effective in conditions driven by IL-6 overproduction such as rheumatoid arthritis and potentially other inflammatory disorders.

Approved indications

• Rheumatoid arthritis (moderate to severe)
• COVID-19 (severe pneumonia)

Common side effects

• Infection (including serious infections)
• Elevated liver enzymes
• Neutropenia
• Hyperlipidemia
• Injection site reactions

Key clinical trials

• Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Placebo to GSK3196165/ Sarilumab CI brief — competitive landscape report
• Placebo to GSK3196165/ Sarilumab updates RSS · CI watch RSS
• GlaxoSmithKline portfolio CI

Frequently asked questions about Placebo to GSK3196165/ Sarilumab

Related

• Drug class: All IL-6 receptor antagonist drugs
• Target: All drugs targeting IL-6R (Interleukin-6 receptor)
• Manufacturer: GlaxoSmithKline — full pipeline
• Therapeutic area: All drugs in Immunology
• Indication: Drugs for Rheumatoid arthritis (moderate to severe)
• Indication: Drugs for COVID-19 (severe pneumonia)
• Compare: Placebo to GSK3196165/ Sarilumab vs similar drugs
• Pricing: Placebo to GSK3196165/ Sarilumab cost, discount & access